A New Drug Candidate (GEMSP) for Multiple Sclerosis

2009 ◽  
Vol 16 (25) ◽  
pp. 3203-3214 ◽  
Author(s):  
Arturo Mangas ◽  
Rafael Covenas ◽  
Dominique Bodet ◽  
Sebastien Duleu ◽  
Michel Geffard
Keyword(s):  
Multiple Sclerosis ◽  
Drug Candidate ◽  
New Drug

Enantioselective Synthesis of Ozanimod, the Active Pharmaceutical Ingredient of a New Drug for Multiple Sclerosis

2021 ◽  
Vol 2021 (12) ◽  
pp. 1924-1930
Author(s):  
Claudio Cianferotti ◽  
Giuseppe Barreca ◽  
Venkatesh Bollabathini ◽  
Luca Carcone ◽  
Damian Grainger ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Active Pharmaceutical Ingredient ◽  
Enantioselective Synthesis ◽  
New Drug

scholarly journals Fexinidazole: A Potential New Drug Candidate for Chagas Disease

2012 ◽  
Vol 6 (11) ◽  
pp. e1870 ◽  
Author(s):  
Maria Terezinha Bahia ◽  
Isabel Mayer de Andrade ◽  
Tassiane Assíria Fontes Martins ◽  
Álvaro Fernando da Silva do Nascimento ◽  
Lívia de Figueiredo Diniz ◽  
...  
Keyword(s):  
Chagas Disease ◽  
Drug Candidate ◽  
New Drug

scholarly journals Antileishmanial Activity of 2-Methoxy-4H-spiro-[naphthalene-1,2′-oxiran]-4-one (Epoxymethoxy-lawsone): A Promising New Drug Candidate for Leishmaniasis Treatment

Molecules ◽  
2018 ◽  
Vol 23 (4) ◽  
pp. 864 ◽  
Author(s):  
Luiz Oliveira ◽  
Franklin Souza-Silva ◽  
Luzia de Castro Côrtes ◽  
Lea Cysne-Finkelstein ◽  
Mirian de Souza Pereira ◽  
...  
Keyword(s):  
Antileishmanial Activity ◽  
Drug Candidate ◽  
New Drug

scholarly journals Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the “weed,” a pharmacodynamic discussion

2016 ◽  
Vol 6 (6) ◽  
pp. 277-284 ◽  
Author(s):  
Douglas Lee Boggs ◽  
Alyssa Peckham ◽  
Angela A. Boggs ◽  
Mohini Ranganathan
Keyword(s):  
Multiple Sclerosis ◽  
Medical Treatment ◽  
New Drug ◽  
Severe Spasticity ◽  
Pharmacologic Activity

Abstract Cannabis is being increasingly used as a medical treatment for a variety of illnesses. However, the cannabis plant has more than 70 different phytocannabinoids with potential pharmacologic activity. Two of the most researched phytocannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Evidence suggests CBD can decrease some of the psychomimetic effects of THC. This has led to the development of a new drug, Nabiximols, for the treatment of moderate to severe spasticity due to multiple sclerosis. A discussion of evidence supporting proposed pharmacodynamic interplay between CBD and THC is presented.

[Ru(phen)2podppz]2+ significantly inhibits glioblastoma growth in vitro and vivo with fewer side-effects than cisplatin

2020 ◽  
Vol 49 (26) ◽  
pp. 8864-8871
Author(s):  
Ruihao Li ◽  
Yabin Ma ◽  
Xiaochun Hu ◽  
Wenjing Wu ◽  
Xuewen Wu ◽  
...  
Keyword(s):  
Side Effects ◽  
Tumor Growth ◽  
Drug Candidate ◽  
Inhibit Tumor Growth ◽  
New Drug

Ru1 could most effectively inhibit tumor growth and avoid any detectable side-effects compared with other ruthenium(ii) complexes and cisplatin, demonstrating its potential to be an exciting new drug candidate for glioblastoma treatment.

New Drug For Multiple Sclerosis

2017 ◽  
Vol 117 (7) ◽  
pp. 22
Author(s):  
Diane S. Aschenbrenner
Keyword(s):  
Multiple Sclerosis ◽  
New Drug
Sign in / Sign up

Export Citation Format

Share Document